NEWAGE INC (NBEV) Fundamental Analysis & Valuation

NASDAQ:NBEV • US6501941032

Current stock price

0.0935 USD
-0.03 (-25.2%)
At close:
0.086 USD
-0.01 (-8.02%)
After Hours:

This NBEV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NBEV Profitability Analysis

1.1 Basic Checks

  • NBEV had negative earnings in the past year.
NBEV Yearly Net Income VS EBIT VS OCF VS FCFNBEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 0 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -1.76%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBEV Yearly ROA, ROE, ROICNBEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 -20 -40 -60 -80

1.3 Margins

Industry RankSector Rank
OM -5.63%
PM (TTM) -1.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NBEV Yearly Profit, Operating, Gross MarginsNBEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. NBEV Health Analysis

2.1 Basic Checks

  • NBEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NBEV has more shares outstanding
  • Compared to 1 year ago, NBEV has an improved debt to assets ratio.
NBEV Yearly Shares OutstandingNBEV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M
NBEV Yearly Total Debt VS Total AssetsNBEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of 0.42, we must say that NBEV is in the distress zone and has some risk of bankruptcy.
  • NBEV has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC8.09%
NBEV Yearly LT Debt VS Equity VS FCFNBEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.42 indicates that NBEV should not have too much problems paying its short term obligations.
  • A Quick Ratio of 0.92 indicates that NBEV may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 0.92
NBEV Yearly Current Assets VS Current LiabilitesNBEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. NBEV Growth Analysis

3.1 Past

  • NBEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.66%, which is quite impressive.
  • NBEV shows a strong growth in Revenue. In the last year, the Revenue has grown by 77.07%.
  • Measured over the past years, NBEV shows a very strong growth in Revenue. The Revenue has been growing by 158.96% on average per year.
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y158.96%
Sales Q2Q%58.78%

3.2 Future

  • Based on estimates for the next years, NBEV will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.05% on average per year.
  • Based on estimates for the next years, NBEV will show a quite strong growth in Revenue. The Revenue will grow by 13.62% on average per year.
EPS Next Y79.08%
EPS Next 2Y36.72%
EPS Next 3Y28.94%
EPS Next 5Y16.05%
Revenue Next Year69.12%
Revenue Next 2Y28.67%
Revenue Next 3Y21.75%
Revenue Next 5Y13.62%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NBEV Yearly Revenue VS EstimatesNBEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NBEV Yearly EPS VS EstimatesNBEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.2 -0.4

More info and screens

Find the best growth stocksShow best growing peers

1

4. NBEV Valuation Analysis

4.1 Price/Earnings Ratio

  • NBEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBEV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBEV Price Earnings VS Forward Price EarningsNBEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.08
NBEV Per share dataNBEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • NBEV's earnings are expected to grow with 28.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y28.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NBEV Dividend Analysis

5.1 Amount

  • NBEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

NBEV Fundamentals: All Metrics, Ratios and Statistics

NEWAGE INC

NASDAQ:NBEV (9/7/2022, 8:44:56 PM)

After market: 0.086 -0.01 (-8.02%)

0.0935

-0.03 (-25.2%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)N/A
Earnings (Next)09-27
Inst Owners0%
Inst Owner Change0%
Ins Owners6.92%
Ins Owner Change0%
Market Cap13.73M
Revenue(TTM)439.49M
Net Income(TTM)-7.13M
Analysts82.86
Price Target3.57 (3718.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.06
P/tB N/A
EV/EBITDA -0.08
EPS(TTM)-0.24
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS2.99
BVpS1.51
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -1.76%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -5.63%
PM (TTM) -1.62%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 0.92
Altman-Z 0.42
F-Score4
WACC8.09%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.82%
EPS Next Y79.08%
EPS Next 2Y36.72%
EPS Next 3Y28.94%
EPS Next 5Y16.05%
Revenue 1Y (TTM)77.07%
Revenue growth 3Y74.95%
Revenue growth 5Y158.96%
Sales Q2Q%58.78%
Revenue Next Year69.12%
Revenue Next 2Y28.67%
Revenue Next 3Y21.75%
Revenue Next 5Y13.62%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NEWAGE INC / NBEV Fundamental Analysis FAQ

What is the fundamental rating for NBEV stock?

ChartMill assigns a fundamental rating of 4 / 10 to NBEV.


What is the valuation status of NEWAGE INC (NBEV) stock?

ChartMill assigns a valuation rating of 3 / 10 to NEWAGE INC (NBEV). This can be considered as Overvalued.


How profitable is NEWAGE INC (NBEV) stock?

NEWAGE INC (NBEV) has a profitability rating of 3 / 10.


Can you provide the financial health for NBEV stock?

The financial health rating of NEWAGE INC (NBEV) is 2 / 10.